Bicycle Therapeutics plc
BCYCHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Bicycle Therapeutics plc (BCYC) is listed under Biotechnology. At a $247.8M market cap, Bicycle Therapeutics plc ranks as a micro-cap company within healthcare. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Market Cap
$247.8M
Beta
1.68
P/E (TTM)
—
P/E (Fwd)
-1.60
EPS (TTM)
$-2.73
EPS (Fwd)
$-2.21
ROE
-32.3%
ROA
-17.9%
Cash
$510.1M
Total Debt
$14.7M
Free CF
-$99.8M
52W Change
-56.3%
Annual Financials
Cash vs Debt
Where BCYC stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BCYC finished 17.10% below its 150-day moving average ($4.27) and 24.68% below its 200-day moving average ($4.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BCYC overbought or oversold?
At the October 20, 2026 close, BCYC's RSI(14) was 47.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $510.1M in cash and $14.7M in debt, BCYC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$99.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -32.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $11.7M (2021) to $72.6M (2025), reflecting a 521% increase over the period.
A beta of 1.68 means BCYC is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, BCYC has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BCYC.